TY - JOUR
T1 - Genes involved in neurodevelopment, neuroplasticity and major depression
T2 - No association for CACNA1C, CHRNA7 and MAPK1
AU - Calabrò, Marco
AU - Mandelli, Laura
AU - Crisafulli, Concetta
AU - Lee, Soo Jung
AU - Jun, Tae Youn
AU - Wang, Sheng Min
AU - Patkar, Ashwin A.
AU - Masand, Prakash S.
AU - Han, Changsu
AU - Pae, Chi Un
AU - Serretti, Alessandro
N1 - Funding Information:
This research was supported by a grant of the Korea Health Technology RandD Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (Grant Number : HC15C1405)
Funding Information:
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number : HC15C1405). All authors declare no personal, financial, or commercial conflicts of interest in relation with this study.
Publisher Copyright:
Copyright © 2019, Korean College of Neuropsychopharmacology.
PY - 2019
Y1 - 2019
N2 - Objective: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of three candidate genes for MDD; calcium voltagegated channel subunit alpha1 C (CACNA1C ), cholinergic receptor nicotinic alpha 7 subunit (CHRNA7 ), and mitogenactivated protein kinase 1 (MAPK1 ). Methods: Two-hundred forty-two MDD patients and 326 healthy controls of Korean ancestry served as samples for the analyses. Thirty-nine single nucleotide polymorphisms (SNPs) within CACNA1C, CHRNA7, and MAPK1 genes were genotyped and subsequently tested for association with MDD (primary analysis) and other clinical features (symptoms' severity, age of onset, history of suicide attempt, treatment outcome) (secondary analyses). Single SNPs, haplotypes and epistatic analyses were performed. Results: Single SNPs were not associated with disease risk and clinical features. However, a combination of alleles (haplotype) within MAPK1 was found associated with MDD-status. Secondary analyses detected a possible involvement of CACNA1C haplotype in resistance to antidepressant treatment. Conclusion: These data suggest a role for MAPK1 and CACNA1C in MDD risk and treatment resistance, respectively. However, since many limitations characterize the analysis, the results must be considered with great caution and verified.
AB - Objective: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of three candidate genes for MDD; calcium voltagegated channel subunit alpha1 C (CACNA1C ), cholinergic receptor nicotinic alpha 7 subunit (CHRNA7 ), and mitogenactivated protein kinase 1 (MAPK1 ). Methods: Two-hundred forty-two MDD patients and 326 healthy controls of Korean ancestry served as samples for the analyses. Thirty-nine single nucleotide polymorphisms (SNPs) within CACNA1C, CHRNA7, and MAPK1 genes were genotyped and subsequently tested for association with MDD (primary analysis) and other clinical features (symptoms' severity, age of onset, history of suicide attempt, treatment outcome) (secondary analyses). Single SNPs, haplotypes and epistatic analyses were performed. Results: Single SNPs were not associated with disease risk and clinical features. However, a combination of alleles (haplotype) within MAPK1 was found associated with MDD-status. Secondary analyses detected a possible involvement of CACNA1C haplotype in resistance to antidepressant treatment. Conclusion: These data suggest a role for MAPK1 and CACNA1C in MDD risk and treatment resistance, respectively. However, since many limitations characterize the analysis, the results must be considered with great caution and verified.
KW - CACNA1C
KW - CHRNA7
KW - Deep phenotyping
KW - MAPK1
KW - Major depressive disorder
UR - http://www.scopus.com/inward/record.url?scp=85072164170&partnerID=8YFLogxK
U2 - 10.9758/cpn.2019.17.3.364
DO - 10.9758/cpn.2019.17.3.364
M3 - Article
AN - SCOPUS:85072164170
SN - 1738-1088
VL - 17
SP - 364
EP - 368
JO - Clinical Psychopharmacology and Neuroscience
JF - Clinical Psychopharmacology and Neuroscience
IS - 3
ER -
